Third Rock-Launched GBT Raises $40.7M in Series A
Global Blood Therapeutics Inc. (GBT) came charging out of the gate Thursday with a $40.7 million Series A, becoming the first company "organically constructed, formed and launched" from the West Coast office of Third Rock Ventures LLC, according to Mark A. Goldsmith, the company's CEO and a Third Rock venture partner.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST